+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Vector Market Forecast to 2033

  • PDF Icon

    Report

  • 120 Pages
  • October 2025
  • Region: Global
  • Grand View Research
  • ID: 6189304
REQUEST CUSTOMIZATION
Description Jump to:
The global gene vector market size was estimated at USD 7.88 billion in 2024 and is projected to reach USD 42.61 billion by 2033, growing at a CAGR of 20.92% from 2025 to 2033. The main growth drivers are the increasing prevalence of genetic disorders, advancements in gene therapy, and a boom in research and development efforts to create innovative gene delivery systems. The market is expected to grow significantly in several important global regions as the need for targeted therapies and personalized medicine keeps growing.

Advancements in Viral and Non-viral Vectors

The global gene vector industry is seeing significant growth due to advancements in viral and non-viral vector technology. Adeno-associated viruses (AAV), lentiviruses, and retroviruses are viral vectors whose safety profiles, transduction efficiency, and tissue-specific targeting have all been greatly enhanced by ongoing innovation. For example, next-generation AAVs are being developed with improved delivery efficiency and decreased immunogenicity, making them ideal for treating inherited and chronic diseases.

The market momentum is being strengthened by the advancements associated with non-viral vectors. Lipid nanoparticles (LNPs), carriers from polymers, and some form of physical delivery, such as electroporation, are increasingly used as alternatives to viral systems because they can be scaled up, have fewer safety concerns, and carry larger genetic payloads. LNPs, specifically, were brought to the forefront of global attention with the COVID-19 pandemic because mRNA vaccines utilized lipid nanoparticles as carriers, further demonstrating their therapeutic potential in the treatment of oncology, rare genetic diseases, and infectious diseases. The dedicated research and development to improve delivery efficiency, reduce cytotoxicity, and improve targeting accuracy of non-viral vectors are still attractive to large-scale commercial manufacturing.

Growing Demand for Personalized Medicine

The rising trend toward personalized medicine is a major growth driver for the gene vector market. Generic, one-size-fits-all treatments often fail to address the underlying cause of complex and rare diseases. This creates a demand for therapy designed for individual patients based on their genetic profile. Gene vectors will be integral to developing these personalized treatments that deliver therapeutic genes directly into targeted cells to help treat the molecular basis of disease, rather than simply addressing symptoms. As advancements in genomic sequencing and biomarker discovery accelerate, healthcare providers are better equipped to design therapies specific to a patient’s genetic makeup, which, in turn, is increasing reliance on viral and non-viral vectors as essential tools in this transformation.

Growing investments in precision medicine initiatives across the globe further underscore this trend. Governments, research institutes, and pharmaceutical companies are focusing on personalized treatment models. They aim to improve patient outcomes, reduce side effects, and make healthcare more cost-effective. Gene and cell therapies, many of which are vector-based, are at the forefront of this movement, with increasing approvals of treatments for cancers, rare genetic disorders, and inherited conditions.

Global Gene Vector Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the global gene vector market on the basis of type, delivery method, therapeutic area, end use, and region:

Type Outlook (Revenue, USD Million, 2021-2033)

  • Viral Vectors
  • Non-Viral Vectors

Delivery Method Outlook (Revenue, USD Million, 2021-2033)

  • In-vivo Gene Delivery
  • Ex-vivo Gene Delivery
  • Others

Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Genetic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Ophthalmological Diseases
  • Others

End Use Outlook (Revenue, USD Million, 2021-2033)

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • CROs & CMOs

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Type
1.2.2. Delivery Method
1.2.3. Therapeutic Area
1.2.4. End use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Details
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Impact Analysis
3.3.1.1. Advancements in viral and non-viral vectors
3.3.1.2. Growing demand for personalized medicine
3.3.2. Market Restraint Impact Analysis
3.3.2.1. Regulatory and compliance challenges
3.4. Business Environment Analysis
3.4.1. PESTLE Analysis
3.4.2. PORTER’S Five Forces Analysis
Chapter 4. Gene Vector Market: Type Business Analysis
4.1. Type Segment Dashboard
4.2. Global Gene Vector Market Type, Movement Analysis
4.3. Global Gene Vector Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Viral Vectors
4.4.1. Global viral vectors market estimates and forecasts, 2021-2033 (USD Million)
4.4.2. Adenoviral Vectors
4.4.2.1. Global adenoviral vectors market estimates and forecasts, 2021-2033 (USD Million)
4.4.3. Adeno-Associated Viral (AAV) Vectors
4.4.3.1. Global adeno-associated viral (AAV) Vectors market estimates and forecasts, 2021-2033 (USD Million)
4.4.4. Lentiviral Vectors
4.4.4.1. Global lentiviral vectors market estimates and forecasts, 2021-2033 (USD Million)
4.4.5. Retroviral Vectors
4.4.5.1. Global retroviral vectors market estimates and forecasts, 2021-2033 (USD Million)
4.4.6. Herpes Simplex Virus (HSV) Vectors
4.4.6.1. Global herpes simplex virus (HSV) Vectors market estimates and forecasts, 2021-2033 (USD Million)
4.4.7. Others
4.4.7.1. Global other viral vectors market estimates and forecasts, 2021-2033 (USD Million)
4.5. Non-Viral Vectors
4.5.1. Global non-viral vectors market estimates and forecasts, 2021-2033 (USD Million)
4.5.2. Plasmid DNA
4.5.2.1. Global plasmid DNA market estimates and forecasts, 2021-2033 (USD Million)
4.5.3. Lipid Nanoparticles
4.5.3.1. Global lipid nanoparticles market estimates and forecasts, 2021-2033 (USD Million)
4.5.4. Polymer-based Vectors
4.5.4.1. Global polymer-based vectors market estimates and forecasts, 2021-2033 (USD Million)
4.5.5. Others
4.5.5.1. Global other non-viral vectors market estimates and forecasts, 2021-2033 (USD Million)
Chapter 5. Gene Vector Market: Delivery Method Business Analysis
5.1. Delivery Method Segment Dashboard
5.2. Global Gene Vector Market Delivery Method, Movement Analysis
5.3. Global Gene Vector Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
5.4. in-vivo Gene Delivery
5.4.1. Global in-vivo gene delivery market estimates and forecasts, 2021-2033 (USD Million)
5.5. Ex-vivo Gene Delivery
5.5.1. Global ex-vivo gene delivery market estimates and forecasts, 2021-2033 (USD Million)
5.6. Others
5.6.1. Global others market estimates and forecasts, 2021-2033 (USD Million)
Chapter 6. Gene Vector Market: Therapeutic Area Business Analysis
6.1. Therapeutic Area Segment Dashboard
6.2. Global Gene Vector Market Therapeutic Area, Movement Analysis
6.3. Global Gene Vector Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
6.4. Oncology
6.4.1. Global oncology market estimates and forecasts, 2021-2033 (USD Million)
6.5. Genetic Diseases
6.5.1. Global genetic disease market estimates and forecasts, 2021-2033 (USD Million)
6.6. Infectious Diseases
6.6.1. Global infectious disease market estimates and forecasts, 2021-2033 (USD Million)
6.7. Cardiovascular Diseases
6.7.1. Global cardiovascular disease market estimates and forecasts, 2021-2033 (USD Million)
6.8. Neurological Diseases
6.8.1. Global neurological disease market estimates and forecasts, 2021-2033 (USD Million)
6.9. Ophthalmological Diseases
6.9.1. Global ophthalmological disease market estimates and forecasts, 2021-2033 (USD Million)
6.10. Others
6.10.1. Global others market estimates and forecasts, 2021-2033 (USD Million)
Chapter 7. Gene Vector Market: End Use Business Analysis
7.1. End Use Segment Dashboard
7.2. Global Gene Vector Market End use, Movement Analysis
7.3. Global Gene Vector Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Pharmaceutical & Biotechnology Companies
7.4.1. Global pharmaceutical & biotechnology companies market estimates and forecasts, 2021-2033 (USD Million)
7.5. Academic & Research Institutes
7.5.1. Global academic & research institutes market estimates and forecasts, 2021-2033 (USD Million)
7.6. CROs & CMOs
7.6.1. Global CROs & CMOs market estimates and forecasts, 2021-2033 (USD Million)
Chapter 8. Gene Vector Market: Regional Estimates and Trend Analysis, by Type, Delivery Method, Therapeutic Area, & End Use
8.1. Regional Dashboard
8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
8.3. North America
8.3.1. North America gene vector market, 2021-2033 (USD Million)
8.3.2. U.S.
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. U.S. gene vector market, 2021-2033 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Canada gene vector market, 2021-2033 (USD Million)
8.3.4. Mexico
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Mexico gene vector market, 2021-2033 (USD Million)
8.4. Europe
8.4.1. Europe gene vector market, 2021-2033 (USD Million)
8.4.2. UK
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. UK gene vector market, 2021-2033 (USD Million)
8.4.3. Germany
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Germany gene vector market, 2021-2033 (USD Million)
8.4.4. France
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. France gene vector market, 2021-2033 (USD Million)
8.4.5. Italy
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Italy gene vector market, 2021-2033 (USD Million)
8.4.6. Spain
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Spain gene vector market, 2021-2033 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Denmark gene vector market, 2021-2033 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Sweden gene vector market, 2021-2033 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Framework
8.4.9.4. Norway gene vector market, 2021-2033 (USD Million)
8.5. Asia-Pacific
8.5.1. Asia-Pacific gene vector market, 2021-2033 (USD Million)
8.5.2. Japan
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Japan gene vector market, 2021-2033 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. China gene vector market, 2021-2033 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. India gene vector market, 2021-2033 (USD Million)
8.5.5. Australia
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Australia gene vector market, 2021-2033 (USD Million)
8.5.6. Thailand
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Thailand gene vector market, 2021-2033 (USD Million)
8.5.7. South Korea
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. South Korea gene vector market, 2021-2033 (USD Million)
8.6. Latin America
8.6.1. Latin America gene vector market, 2021-2033 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Brazil gene vector market, 2021-2033 (USD Million)
8.6.3. Argentina
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Argentina gene vector market, 2021-2033 (USD Million)
8.7. MEA
8.7.1. MEA gene vector market, 2021-2033 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. South Africa gene vector market, 2021-2033 (USD Million)
8.7.3. Saudi Arabia
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Saudi Arabia gene vector market, 2021-2033 (USD Million)
8.7.4. UAE
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. UAE gene vector market, 2021-2033 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Kuwait gene vector market, 2021-2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Charles River Laboratories
9.4.1.1. Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. VGXI, Inc.
9.4.2.1. Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Danaher (Aldevron)
9.4.3.1. Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Kaneka Corp.
9.4.4.1. Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Eurofins Genomics
9.4.5.1. Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Cell and Gene Therapy Catapult
9.4.6.1. Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Catalent, Inc.
9.4.7.1. Overview
9.4.7.2. Product Benchmarking
9.4.7.3. Strategic Initiatives
9.4.8. Lonza
9.4.8.1. Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Luminous BioSciences, LLC
9.4.9.1. Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Akron Biotech
9.4.10.1. Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 4. Global Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 5. Global Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 6. Global Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 7. Global Gene Vector Market, by Region, 2021-2033 (USD Million)
Table 8. North America Gene Vector Market, by Country, 2021-2033 (USD Million)
Table 9. North America Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 10. North America Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 11. North America Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 12. North America Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 13. U.S. Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 14. U.S. Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 15. U.S. Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 16. U.S. Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 17. Canada Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 18. Canada Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 19. Canada Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 20. Canada Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 21. Mexico Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 22. Mexico Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 23. Mexico Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 24. Mexico Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 25. Europe Gene Vector Market, by Country, 2021-2033 (USD Million)
Table 26. Europe Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 27. Europe Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 28. Europe Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 29. Europe Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 30. Germany Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 31. Germany Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 32. Germany Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 33. Germany Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 34. UK Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 35. UK Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 36. UK Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 37. UK Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 38. France Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 39. France Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 40. France Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 41. France Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 42. Italy Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 43. Italy Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 44. Italy Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 45. Italy Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 46. Spain Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 47. Spain Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 48. Spain Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 49. Spain Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 50. Denmark Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 51. Denmark Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 52. Denmark Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 53. Denmark Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 54. Norway Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 55. Norway Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 56. Norway Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 57. Norway Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 58. Sweden Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 59. Sweden Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 60. Sweden Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 61. Sweden Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 62. Asia-Pacific Gene Vector Market, by Country, 2021-2033 (USD Million)
Table 63. Asia-Pacific Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 64. Asia-Pacific Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 65. Asia-Pacific Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 66. Asia-Pacific Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 67. China Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 68. China Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 69. China Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 70. China Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 71. Japan Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 72. Japan Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 73. Japan Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 74. Japan Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 75. India Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 76. India Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 77. India Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 78. India Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 79. South Korea Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 80. South Korea Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 81. South Korea Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 82. South Korea Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 83. Australia Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 84. Australia Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 85. Australia Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 86. Australia Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 87. Thailand Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 88. Thailand Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 89. Thailand Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 90. Thailand Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 91. Latin America Gene Vector Market, by Country, 2021-2033 (USD Million)
Table 92. Latin America Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 93. Latin America Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 94. Latin America Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 95. Latin America Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 96. Brazil Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 97. Brazil Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 98. Brazil Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 99. Brazil Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 100. Argentina Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 101. Argentina Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 102. Argentina Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 103. Argentina Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 104. Middle East and Africa Gene Vector Market, by Country, 2021-2033 (USD Million)
Table 105. Middle East and Africa Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 106. Middle East and Africa Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 107. Middle East and Africa Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 108. Middle East and Africa Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 109. South Africa Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 110. South Africa Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 111. South Africa Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 112. South Africa Gene Vector Market, by End use, 2021-2033 (USD Million)
Table 113. Saudi Arabia Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 114. Saudi Arabia Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 115. Saudi Arabia Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 116. Saudi Arabia Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 117. UAE Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 118. UAE Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 119. UAE Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 120. UAE Gene Vector Market, by End Use, 2021-2033 (USD Million)
Table 121. Kuwait Gene Vector Market, by Type, 2021-2033 (USD Million)
Table 122. Kuwait Gene Vector Market, by Delivery Method, 2021-2033 (USD Million)
Table 123. Kuwait Gene Vector Market, by Therapeutic Area, 2021-2033 (USD Million)
Table 124. Kuwait Gene Vector Market, by End Use, 2021-2033 (USD Million)
List of Figures
Figure 1 Gene vector market segmentation
Figure 2 Data analysis models
Figure 3 Market formulation and validation
Figure 4 Data validation & publishing
Figure 5 Market research process
Figure 6 Information procurement
Figure 7 Primary research
Figure 8 Value-chain-based sizing & forecasting
Figure 9 QFD modelling for market share assessment
Figure 10 Market formulation & validation
Figure 11 Commodity flow analysis
Figure 12 Market outlook
Figure 13 Segment snapshot-1
Figure 14 Competitive landscape snapshot
Figure 15 Market trends & outlook
Figure 16 PESTEL analysis
Figure 17 Porter’s five forces analysis
Figure 18 Gene vector market: Type outlook key takeaways
Figure 19 Gene vector market: Type movement analysis
Figure 20 Viral vectors market, 2021-2033 (USD Million)
Figure 21 Non-viral vectors market, 2021-2033 (USD Million)
Figure 22 Gene vector market: Delivery Method outlook key takeaways
Figure 23 Gene vector market: Delivery Method movement analysis
Figure 24 in-vivo gene delivery, 2021-2033 (USD Million)
Figure 25 Ex-vivo gene delivery, 2021-2033 (USD Million)
Figure 26 Others, 2021-2033 (USD Million)
Figure 27 Gene vector market: Therapeutic Area outlook key takeaways
Figure 28 Gene vector market: Therapeutic Area movement analysis
Figure 29 Oncology, 2021-2033 (USD Million)
Figure 30 Genetic Diseases, 2021-2033 (USD Million)
Figure 31 Infectious Diseases, 2021-2033 (USD Million)
Figure 32 Cardiovascular Diseases, 2021-2033 (USD Million)
Figure 33 Neurological Diseases, 2021-2033 (USD Million)
Figure 34 Ophthalmological Diseases, 2021-2033 (USD Million)
Figure 35 Others, 2021-2033 (USD Million)
Figure 36 Gene vector market: End use outlook key takeaways
Figure 37 Gene vector market: End use movement analysis
Figure 38 Pharmaceutical & biotechnology companies market, 2021-2033 (USD Million)
Figure 39 Academic & research institutions market, 2021-2033 (USD Million)
Figure 40 CROs & CMOs market, 2021-2033 (USD Million)
Figure 41 Regional marketplace outlook, 2024 & 2033 (USD Million)
Figure 42 Regional marketplace: Key takeaways
Figure 43 North America gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 44 Key country dynamics
Figure 45 U.S. gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 46 Key country dynamics
Figure 47 Canada gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 48 Key country dynamics
Figure 49 Mexico gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 50 Europe gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 51 Key country dynamics
Figure 52 Germany gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 53 Key country dynamics
Figure 54 UK gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 55 Key country dynamics
Figure 56 France gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 57 Key country dynamics
Figure 58 Italy gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 59 Key country dynamics
Figure 60 Spain gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 61 Key country dynamics
Figure 62 Denmark gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 63 Key country dynamics
Figure 64 Sweden gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 65 Key country dynamics
Figure 66 Norway gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 67 Asia-Pacific gene vector market estimates and forecast, 2021-2033 (USD Million)
Figure 68 Key country dynamics
Figure 69 Japan gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 70 Key country dynamics
Figure 71 China gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 72 Key country dynamics
Figure 73 India gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 74 Key country dynamics
Figure 75 South Korea gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 76 Key country dynamics
Figure 77 Australia gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 78 Key country dynamics
Figure 79 Thailand gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 80 Latin America gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 81 Key country dynamics
Figure 82 Brazil gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 83 Key country dynamics
Figure 84 Argentina gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 85 MEA gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 86 Key country dynamics
Figure 87 South Africa gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 88 Key country dynamics
Figure 89 Saudi Arabia gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 90 Key country dynamics
Figure 91 UAE gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 92 Key country dynamics
Figure 93 Kuwait gene vector market estimates and forecasts, 2021-2033 (USD Million)
Figure 94 Market position analysis
Figure 95 Market participant categorization
Figure 96 Strategic framework

Companies Mentioned

The companies profiled in this Gene Vector market report include:
  • Charles River Laboratories
  • VGXI, Inc.
  • Danaher (Aldevron)
  • Kaneka Corp.
  • Catalent Inc.
  • Cell and Gene Therapy Catapult
  • Eurofins Genomics
  • Lonza
  • Luminous BioSciences, LLC
  • Akron Biotech

Table Information

Report AttributeDetails
No. of Pages120
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 7.88 Billion
Forecasted Market Value ( USD ) by 2033 $ 42.61 Billion
Compound Annual Growth Rate20.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gene Therapy Media Market Size, Share & Trends Analysis Report by Product (Specialty Media, Serum-free Media), Vector Type (AAV, LV), End Use, and Region with Growth Forecasts, 2026-2033 - Product Image

Gene Therapy Media Market Size, Share & Trends Analysis Report by Product (Specialty Media, Serum-free Media), Vector Type (AAV, LV), End Use, and Region with Growth Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
North America, Europe & Asia-Pacific Gene Therapy Cell Culture Media Market Forecast to 2033 - Product Image

North America, Europe & Asia-Pacific Gene Therapy Cell Culture Media Market Forecast to 2033

  • Report
  • 150 Pages
  • Asia Pacific, Europe, ... Asia Pacific, Europe, North America
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
U.S. Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2025 - 2033

  • Report
  • 120 Pages
  • United States
From
U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), Indication (Oncology, Infectious Diseases), and Growth Forecasts, 2025-2033 - Product Image

U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), Indication (Oncology, Infectious Diseases), and Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.